Altesa BioSciences
PrivateLast Round
Series B
Feb 19, 2026
Est. Valuation
$190M
Total Funding Raised
$153M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Altesa BioSciences operates in Healthcare & Life Sciences and is based in College Park, Georgia. Its latest recorded funding round was a Series B round in February 2026.
Altesa BioSciences is a biotechnology company that develops antiviral drugs to treat respiratory infections and chronic lung diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Altesa BioSciences Comparables
Compare Altesa BioSciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ansun BioPharma | 83% | |
| Eradivir | 74% | |
| TrippBio, Inc. | 73% |
For institutional investors. Book with your work email.
Altesa BioSciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Feb 19, 2026 | ||||
| Series A | Jul 1, 2023 | ||||
| Series A | Jan 5, 2023 | ||||
| Seed | Feb 10, 2022 | ||||
| Seed | Jan 1, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Altesa BioSciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series B |
| Forbion | Series B |
| Georgia Research Alliance | Series A, Seed |
| Atlantic Partners | Series B |
| Medicxi | Series B, Series A |
| Pitango Venture Capital | Series B, Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 18, 2026
Grew 16% QoQ, from 19 to 22 employees.
- Jul 26, 2026
Grew 17% QoQ, from 18 to 21 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_awardAug 25, 2026
Altesa BioSciences, Inc. receives the 2026 Georgia Life Sciences Golden Helix Award for Deal of the Year from Georgia Life Sciences at the Georgia Life Sciences Summit Golden Helix Awards ceremony in Georgia on Aug 25th '26, recognizing its $75 million Series B financing to advance vapendavir.
For institutional investors. Book with your work email.
Altesa BioSciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Altesa BioSciences's valuation, stock price, and market status.
Is Altesa BioSciences a public or private company?
Altesa BioSciences is a private company.
What is the current stock price of Altesa BioSciences?
Altesa BioSciences is a private company, so its shares have no public market price. Caplight tracks Altesa BioSciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Altesa BioSciences worth (valuation)?
Altesa BioSciences's valuation is estimated at $190.0M based on funding round data.
Can I buy Altesa BioSciences stock?
Altesa BioSciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Altesa BioSciences's last funding round?
Altesa BioSciences's most recent funding round was Series B on February 19, 2026.
Who are the main investors in Altesa BioSciences?
Key investors in Altesa BioSciences include Forbion Capital Partners, Forbion, Pitango Venture Capital.
Will Altesa BioSciences IPO soon?
No public IPO plans have been announced for Altesa BioSciences.
How can I track Altesa BioSciences secondary market activity?
Caplight tracks bids, offers, and trades in Altesa BioSciences's shares on secondary markets.